CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells

BACKGROUND: The ability of CRISPR/Cas9 to mutate any desired genomic locus is being increasingly explored in the emerging area of cancer immunotherapy. In this respect, current efforts are mostly focused on the use of autologous (i.e. patient-derived) T cells. The autologous approach, however, has d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamali, Elahe, Rahbarizadeh, Fatemeh, Hojati, Zohreh, Frödin, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844963/
https://www.ncbi.nlm.nih.gov/pubmed/33514392
http://dx.doi.org/10.1186/s12896-020-00665-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844963/
https://www.ncbi.nlm.nih.gov/pubmed/33514392
http://dx.doi.org/10.1186/s12896-020-00665-4

Ejemplares similares